Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 14,943 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Withdrawn Not applicable Interventional

Vitamin D Treatment in Ulcerative Colitis

NCT01640496
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vitamin D3, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 28, 2026, 10:26 AM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)

NCT04941742
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 28, 2026, 10:26 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

NCT05223673
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Futuximab/modotuximab, Trifluridine/Tipiracil
Biological · Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 28, 2026, 10:26 AM EDT
Withdrawn No phase listed Observational

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

NCT01028183
View directory record Official record
Conditions
Gastroesophageal Reflux, Presumed Sepsis, Patent Ductus Arteriosus, Chronic Lung Disease, Neurodevelopmental Impairment
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 5 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 28, 2026, 10:26 AM EDT
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 10:26 AM EDT
Terminated Phase 4 Interventional

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

NCT00274495
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Fatty Liver
Interventions
Rosiglitazone and Pegasys/Ribavirin
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 28, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

NCT07612046
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer
Interventions
MRI, Endoscopic ultrasound
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 28, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

Mayo Clinic Upper Digestive Disease Survey

NCT02530983
View directory record Official record
Conditions
Esophageal Neoplasms, Cancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer, Esophagus Cancer, Neoplasm, Esophageal, Esophagectomy, Abnormalities, Digestive System, Digestive System Abnormalities
Interventions
Mayo Clinic Upper Digestive Disease Survey on Paper, Upper Digestive Disease (UDD Monitor) App
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stepped Care Treatment for Binge-Eating

NCT00965705
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Therapy
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 28, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

Prostate Cancer Genetic Risk Evaluation and Screening Study

NCT05129605
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions
Prostate cancer screening
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 74 Years · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

NCT00809094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 10:26 AM EDT
Completed No phase listed Observational

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF

NCT02109822
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 28, 2026, 10:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

NCT04406831
View directory record Official record
Conditions
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
Interventions
Blood draw
Procedure
Lead sponsor
Nuvance Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 10:26 AM EDT
Completed No phase listed Observational

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

NCT01161953
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Genetic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 28, 2026, 10:26 AM EDT
Not listed No phase listed Observational

Continuous Alcohol Monitoring for Pancreatitis

NCT04350996
View directory record Official record
Conditions
Pancreatitis, Alcohol Drinking
Interventions
Wearable alcohol sensor
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

NCT02300103
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
San Diego, California • San Marcos, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 10:26 AM EDT
Active, not recruiting Not applicable Interventional Results available

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

NCT02293954
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer, Pancreatic Cancer, Rectal Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
radionuclide imaging, positron emission tomography, laboratory biomarker analysis, pharmacological study, Cu 64 anti-CEA monoclonal antibody M5A IV
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 10:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03190941
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 28, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

NCT00583531
View directory record Official record
Conditions
Pouchitis
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Phase 2 Interventional

Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel

NCT00006245
View directory record Official record
Conditions
Esophageal Cancer
Interventions
alvocidib, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Peroral Endoscopic Myotomy (POEM) for Esophageal Motility

NCT02314741
View directory record Official record
Conditions
Achalasia
Interventions
POEM Procedure
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 28, 2026, 10:26 AM EDT